Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2291]

Highlights of ESMO 2016

Dr Andrés Cervantes - ESMO 2016 Scientific Chair

Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )

Advances for NSCLC in review

Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland

Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )

Pembrolizumab plus chemo as firstline therapy for NSCLC

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

Dr Giorgio Scagliotti - University of Turin, Turin, Italy

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )

KRAS in the clinic and conference

Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

KRAS in the clinic and conference ( Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Phase I results of a novel FGFR inhibitor

Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland

Phase I results of a novel FGFR inhibitor ( Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland )

Firstline pembrolizumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Firstline pembrolizumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer

Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France

Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer ( Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France )

FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer

Prof John Robertson - University of Nottingham, Nottingham, UK

FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer ( Prof John Robertson - University of Nottingham, Nottingham, UK )

Ribociclib improves progression-free survival in advanced breast cancer

Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center...

Ribociclib improves progression-free survival in advanced breast cancer ( Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US )

Ipilimumab as adjuvant therapy improves OS in high risk melanoma

Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France

Ipilimumab as adjuvant therapy improves OS in high risk melanoma ( Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France )

A novel biomarker for paediatic tumours

Dr Kathleen Birley - UCL Institute of Child Health, London, UK

A novel biomarker for paediatic tumours ( Dr Kathleen Birley - UCL Institute of Child Health, London, UK )

More from ecancer